Harrow, Inc. (NASDAQ:HROW) Shares Sold by Bard Associates Inc.

Bard Associates Inc. lessened its holdings in shares of Harrow, Inc. (NASDAQ:HROW) by 14.5% in the 3rd quarter, HoldingsChannel reports. The firm owned 58,700 shares of the company’s stock after selling 9,980 shares during the quarter. Bard Associates Inc.’s holdings in Harrow were worth $2,639,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also modified their holdings of HROW. Huntington National Bank acquired a new stake in Harrow in the 3rd quarter worth about $164,000. Oppenheimer & Co. Inc. acquired a new stake in shares of Harrow during the 3rd quarter worth about $1,267,000. Corrado Advisors LLC acquired a new position in shares of Harrow in the 3rd quarter worth approximately $331,000. Principal Financial Group Inc. purchased a new position in shares of Harrow during the third quarter worth $329,000. Finally, Hills Bank & Trust Co acquired a new stake in shares of Harrow during the third quarter worth about $107,000. Institutional investors and hedge funds own 72.76% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Craig Hallum increased their price target on Harrow from $45.00 to $65.00 and gave the company a “buy” rating in a research report on Friday, October 4th. Lake Street Capital increased their price target on shares of Harrow from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Friday, October 4th. Finally, B. Riley reissued a “buy” rating and issued a $50.00 target price on shares of Harrow in a report on Thursday, August 29th.

Harrow Price Performance

Shares of Harrow stock opened at $42.86 on Friday. The company has a quick ratio of 2.43, a current ratio of 2.60 and a debt-to-equity ratio of 3.18. The company has a 50-day moving average of $47.84 and a two-hundred day moving average of $32.00. Harrow, Inc. has a 12-month low of $7.81 and a 12-month high of $59.23.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.